Micromet has received Orphan Drug Designation from the European Medicines Agency (EMEA) for BiTE antibody blinatumomab (MT103), for acute lymphoblastic leukemia (ALL).
Blinatumomab is a novel therapeutic antibody that activates a patient’s T cells to seek out and destroy cancer cells.
Micromet, in June, achieved its primary endpoint in an ongoing phase 2 study of acute lymphoblastic leukemia (ALL) patients. The data showed 81% response rate in ALL patients with minimal residual disease (MRD), said the company.
Micromet is a biopharmaceutical company engaged in developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases.
BiTE antibodies represent a new class of antibodies that activate the T cells of a patient’s immune system to eliminate cancer cells.